Lower R&D costs, strategic plans for clinical trials, future commercialization with companies in the US and EUROPE, a solid foundation in scientific intellectual capital and technical framework ensuring world class quality standards have already given the Indian pharmaceutical companies a head start over their global counterparts.

• Indian Biologics market accounts for 62% of $ 3 billion revenue by the Biotechnology industry as a whole.
• In 2012, the Indian Biopharmaceuticals market was worth nearly $ 2 billion and is showing further significant growth.
• In India, about 20 companies are developing Biosimilars.Approximately 50 products are available in the domestic market.
• Several Indian companies are in the process of developing a large portfolio of Biologics & Biosimilars